Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Several key aspects differentiate our library:
partner
Reaxense
upacc
Q8TE69
UPID:
EOLA1_HUMAN
Alternative names:
Endothelial-overexpressed lipopolysaccharide-associated factor 1; Endothelium and lymphocyte associated ASCH domain 1
Alternative UPACC:
Q8TE69; A0A0A0MTB5; A8K784; B7Z6H6; B7ZL96; D6RA72; E7ENU3; Q2M3E9
Background:
Protein EOLA1, also known as Endothelial-overexpressed lipopolysaccharide-associated factor 1 and Endothelium and lymphocyte associated ASCH domain 1, plays a crucial role in cell protection during inflammatory responses. It achieves this by negatively regulating IL6 production and apoptosis in epithelial cells through the modulation of MT2A expression.
Therapeutic significance:
Understanding the role of Protein EOLA1 could open doors to potential therapeutic strategies, particularly in managing inflammatory diseases by targeting its regulatory mechanisms on IL6 production and apoptosis.